HuidaGene Receives FDA Clinical Clearance for HG202 in Neovascular AMD Treatment
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving clinical clearance from the US Food...
HuidaGene Biotechnology
HuidaGene Secures Patent for Innovative CRISPR-Cas12i System in China
HuidaGene (Shanghai) Biotechnology Co., Ltd, a China-based biotech firm, has secured patent approval from the...
HuidaGene and Synthego Form Strategic Partnership for CRISPR-Based Therapies
HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into...
HuidaGene’s MECP2 Duplication Syndrome Therapy Earns Positive EMA Opinion
HuidaGene (Shanghai) Biotechnology Co., Ltd, a biotech company based in China, has announced that it...
HuidaGene Receives FDA Rare Pediatric Disease Designation for MECP2 Syndrome Therapy
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced that it has received Rare Pediatric Disease...
HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm...
HuidaGene Receives CDE IND Approval for Ophthalmology Gene Therapy HG004
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...
HuidaGene Receives FDA IND Approval for Ophthalmology Gene Therapy HG004
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...